The role of XRCC4 in carcinogenesis and anticancer drug discovery.
In the past decades, the incidence of cancer keeps its rapid increasing step all over the world and cancer is always an important threat to public health. It is believed that cancer is resulted from a series of genetic alterations leading to progressive disorder of the normal mechanisms controlling cell proliferation, differentiation, death, and/or genomic stability. The response of the cell to genetic injury and its ability to maintain genomic stability by means of a variety of DNA repair mechanisms are therefore essential in preventing tumor initiation and progression. From the same viewpoint, the relative role of DNA repair as a biomarker for prognosis, predicator of drug and therapy responses, or indeed as target for novel gene therapy is recently patented and very promising. In this review, we have summarized the studies investigating the association between XRCC4, one of the NHEJ genes, and the susceptibility to multiple cancers, and discussed its role in carcinogenesis and application in anticancer drug discovery.
Wu
Cheng-Nan
CN
Department of Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan, ROC.
Liang
Shiu-Yun
SY
Tsai
Chia-Wen
CW
Bau
Da-Tian
DT
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004260:DNA Repair; D004268:DNA-Binding Proteins / Q000187:drug effects* / Q000378:metabolism; D016503:Drug Delivery Systems; D055808:Drug Discovery; D015316:Genetic Therapy / Q000379:methods; D023281:Genomics; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide
D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; C101467:XRCC4 protein, human